Tokyo, Japan and London, UK, 12 November 2019 – Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated results for the nine months ended 30 September 2019. The full report can be accessed by clicking here.
Operational Highlights for Q3 2019
Post Q3 Events
Financial Highlights for the Nine-month Period ended 30 September 2019
* Convenience conversion to USD at the following rates: 2019: 1USD =109.13 JPY; 2018: 1USD =111.12 JPY
Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, commented: “We are delighted with progress made during the third quarter in executing our strategy, which is focused on achieving sustainable profitability through drug discovery and partnering. The recent collaborations with Genentech and Takeda are great examples of this strategy in action and further increase the diversity of projects for which our GPCR-focused drug discovery platform is being applied. Our R&D day in September provided a fantastic showcase of this platform and demonstrated how we are continuing to extend its capabilities through the integration of cutting-edge technologies and expertise. We believe that this strategy will enhance both our ability to generate novel molecules and to create further strategic partnering opportunities as we focus on delivering shareholder value.”
Abbreviations used: CRO – Contract Research Organization; DLB – dementia with Lewy bodies; GPCR – G protein-coupled receptors; PMDA - Pharmaceuticals and Medical Devices Agency
– ENDS –
[1] Non-IFRS measure
[2] Non-IFRS measure